GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2010

Evotec Inks Anemia Drug Discovery Agreement with Vifor Pharma

  • Vifor Pharma could pay Evotec over €5.5 million (about $7.67 million) as part of a deal centered on the search for a new preclinical candidate to treat anemia. The agreement will leverage Evotec’s integrated biology, chemistry, and preclinical development expertise. Evotec will be responsible for all discovery activities and project management, in return for research funding and success-based milestone payments.

    “This agreement represents a great step forward in our business model, as we are committed to identifying a preclinical candidate within an agreed budget,” states Werner Lanthaler, Ph.D., Evotec CEO. “This will allow us to fully integrate and leverage all of our research sites and scientists to efficiently deliver a preclinical candidate to Vifor Pharma.”

    Vifor Pharma is the pharmaceuticals business of the Galenica Group. The company operates in both the prescription pharmaceutical and OTC product markets. Vifor’s prescription drug unit is focused on the development of new products for anemia but is also active in the fields of kidney and autoimmune diseases.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?